Nyxoah S.A.

NasdaqGM NYXH

Nyxoah S.A. Market Capitalization on January 14, 2025: USD 348.82 M

Nyxoah S.A. Market Capitalization is USD 348.82 M on January 14, 2025, a 121.35% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Nyxoah S.A. 52-week high Market Capitalization is USD 716.32 M on March 18, 2024, which is 105.36% above the current Market Capitalization.
Nyxoah S.A. 52-week low Market Capitalization is USD 148.04 M on January 17, 2024, which is -57.56% below the current Market Capitalization.
Nyxoah S.A. average Market Capitalization for the last 52 weeks is USD 363.01 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqGM: NYXH

Nyxoah S.A.

CEO	Mr. Olivier Taelman
IPO Date	April 28, 2021
Location	Belgium
Headquarters	Rue Edouard Belin 12
Employees	146
Sector	Health Care
Industries Pharmaceuticals Telehealth

Description

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Key trends

Past 5 years